Ceramide Detection Methods
Why Species Resolution Is the Requirement
Ceramide synthases produce species with different acyl chains, and the biological effects differ by chain length. C16 ceramide, produced largely by CerS6, is the species most consistently associated with metabolic injury; C24 species are structural components of membranes; C18 has different downstream effects again.
| Species group | Produced mainly by | Reported association |
|---|---|---|
| C14–C16 | CerS5, CerS6 | Metabolic injury, insulin resistance |
| C18 | CerS1, CerS4 | Context-dependent |
| C20–C26 | CerS2, CerS4 | Membrane structure; very-long-chain |
Important distinction. A total ceramide measurement is a sum with the species information removed. Two conditions with identical totals and different species distributions have different biology, and the total cannot distinguish them. This is the single reason the ceramide literature is so inconsistent.
Part 1 — The Methods
| Method | Species resolution | Quantification | Practical note |
|---|---|---|---|
| Targeted LC-MS/MS with isotope-labelled internal standards | Yes | Absolute | The current standard |
| LC-MS without internal standards | Yes | Relative only | Comparable within a batch |
| Shotgun lipidomics | Yes | Semi-quantitative | Good coverage; ion suppression |
| TLC with densitometry | Class-level | Relative | Historical; being phased out |
| Antibody-based "ceramide" ELISA or dot blot | No | Bulk signal | Cross-reactivity; not recommended for quantification |
| Ceramide kinase-coupled assay | Total by class | Relative | Specific for ceramide but not species |
Readout note. The choice of internal standard matters. A single non-physiological species (commonly C17 ceramide) is adequate for most species if the extraction recovery is uniform across chain lengths, but recovery varies with hydrophobicity, so a panel of standards is preferable for the full C14–C26 range.
Part 2 — Sample Preparation
| Step | Requirement | Consequence if omitted |
|---|---|---|
| Quench | Cold, immediate | Sphingolipid interconversion continues after harvest |
| Internal standard | Added before extraction | Recovery cannot be corrected |
| Extraction | Acidified organic solvent, or a validated biphasic method | Low recovery; matrix effects |
| Phase separation | Complete; aqueous removal | Salt and protein interference |
| Drying and resuspension | In injection solvent | Precipitation of long-chain species |
| Storage | −80 °C under inert gas, if delayed | Oxidation of unsaturated species |
Caveat on acid. Strong acid can hydrolyse sphingomyelin to ceramide, producing a false increase. Acidified extraction is used deliberately for some analytes and inadvertently for others; the protocol should state which, and a sphingomyelin-spike control will reveal hydrolysis.
Part 3 — What to Report
A defensible ceramide dataset reports:
- • At least seven species: C14, C16, C18, C20, C22, C24:0, C24:1.
- • Dihydroceramides alongside, because the dihydroceramide/ceramide ratio reports desaturase activity.
- • Sphingosine and sphinganine, because they indicate the salvage route and fumonisin exposure respectively.
- • Sphingomyelin species for at least the dominant chains, to show whether the change is hydrolysis-derived.
- • Protein or cell-count normalisation, stated.
- • Recovery, from the internal standards.
Important distinction. Sphinganine accumulation is the signature of ceramide synthase inhibition and is the expected result of fumonisin treatment. A study using fumonisin to lower ceramide that does not report sphinganine has not shown what it thinks it has shown.
Part 4 — Interpreting a Species Change
| Pattern | Suggests | Confirm with |
|---|---|---|
| C16 up, others unchanged | CerS6 activity or substrate supply | CerS6 perturbation; palmitate supply |
| All species up proportionally | Increased de novo flux | Serine or palmitate labelling |
| Long chains down, short chains up | CerS2 loss or a shift in substrate | CerS2 expression; acyl-CoA profile |
| Ceramide up with sphingomyelin down | Sphingomyelinase activity | Isoform-specific inhibition; sphingomyelin species |
| Dihydroceramide up with ceramide flat | Desaturase limitation | DES expression; labelling |
Part 5 — Common Failures
- • Total ceramide reported as the finding.
- • Antibody-based bulk assays used for quantification.
- • No internal standard, so recovery and matrix effects are unmeasured.
- • Only one or two species reported, when the claim concerns a specific chain length.
- • Sphinganine not measured in a fumonisin experiment.
- • Sphingomyelin not measured, so hydrolysis cannot be excluded.
- • Acid hydrolysis during extraction producing a false increase.
- • Normalisation to protein in a model where protein content changes with lipid load.
Part 6 — Where This Article Connects
This is the analytical companion to the sphingolipid article, which covers the routes and the isoform logic. The phospholipid article covers the membrane context in which ceramide acts, and the palmitate delivery article covers the substrate supply that determines which species can be made.
If you need ceramide measured as a species panel with recovery and sphingomyelin controls, we can scope the analysis with you.
Contact EDITGENE to request a project consultation or quote.
Scientific scope and validation note
Species distribution, recovery and ionisation efficiency vary by matrix, instrument and standards used; the panel described here is a minimum, not a fixed method.
A total ceramide value does not establish which species changed, and a species change does not establish the route that produced it.
Scientific interpretation and experimental design
- • Species, not totals. Chain length determines the biology.
- • Internal standards are required for quantification.
- • Acid can hydrolyse sphingomyelin. Control for it.
- • Report sphinganine when using fumonisin.
- • Report dihydroceramides to see the desaturase step.
- • Recovery is part of the result.
Selected references for further reading
- • Merrill AH Jr, et al. Sphingolipid analysis by HPLC–tandem mass spectrometry. Methods in Enzymology. 2005;393:224–243.
- • Hannun YA, Obeid LM. Sphingolipids and their metabolism in physiology and disease. Nature Reviews Molecular Cell Biology. 2018;19:175–191.
- • Turpin-Nolan SM, et al. CerS6-derived C16:0 ceramide promotes the development of obesity and insulin resistance. Cell Metabolism. 2020;31:1–14.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PBRM1 Knockout A-549 Cell Line | EDJ0001-K01 | Human | 55193 | Details Get a Quote |
| YTHDC1 Knockout A-549 Cell Line | EDC07652 | Human | 91746 | Details Get a Quote |
| TP53 Knockout HCT 116 Cell Line | EDC07854 | Human | 7157 | Details Get a Quote |
| Sirt2 Knockout MH-S Cell Line | EDJ-KQ78173 | Mouse | 64383 | Details Get a Quote |
| TFE3 Knockout KGN Cell Line | EDJ-KQ48 | Human | 7030 | Details Get a Quote |
| Stub1 Knockout MB49 Cell Line | EDJ-KQ53 | Mouse | 56424 | Details Get a Quote |
| ARID1A Knockout SNK-6 Cell Line | EDJ-KQ64 | Human | 8289 | Details Get a Quote |
| Tet1 Knockout Kupffer Cell Line | EDJ-KQ88 | Mouse | 52463 | Details Get a Quote |
| NR1H3 Knockout HEK293T Cell Line | EDJ-KQ109 | Human | 10062 | Details Get a Quote |
| NR1H2 Knockout HEK293T Cell Line | EDJ-KQ110 | Human | 7376 | Details Get a Quote |
| RPS6KB2 Knockout HEK293 Cell Line | EDJ-KQ125 | Human | 6199 | Details Get a Quote |
| SMAD6 Knockout HEK293 Cell Line | EDJ-KQ126 | Human | 4091 | Details Get a Quote |
| JUN Knockout HEK293 Cell Line | EDJ-KQ176 | Human | 3725 | Details Get a Quote |
| JUN Knockout HEK293T Cell Line | EDJ-KQ184 | Human | 3725 | Details Get a Quote |
| ALKBH5 Knockout HEK293 Cell Line | EDJ-KQ186 | Human | 54890 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »